Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT06562582
Recruiting Phase 4

STunning in Acute Myocardial Infarction - BAS

NCT06562582 · tracked via the Priya Life Science Sweden tracker
Sponsor
Vastra Gotaland Region
Phase
Phase 4
Started
2025-01-06
Last updated
2025-06-27

Condition(s) studied

Myocardial Infarct

Investigational drug(s) / intervention(s)

Bisoprolol Oral Tablet →Ramipril Oral ProductDapagliflozin Oral Product

Bisoprolol Oral Tablet: Timing of drug intervention after PCI

Ramipril Oral Product: Timing of drug intervention after PCI

Dapagliflozin Oral Product: Timing of drug intervention after PCI

Study summary

The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium/glucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI)

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients with STEMI who undergo primary PCI within 6 hours of symptom onset (Excluding prodromal symptoms) 2. Informed consent Exclusion Criteria: 1. Killip class ≥ 3 2. Chronic kidney disease with GFR \< 25 ml/min/1.73 m2 3. Pre-existing non-reversible cardiac dysfunction or heart failure 4. Current treatment with any beta blocker, RAAS inhibitor or SGLT2 inhibitor 5. Absolute or relative contraindication to any one of the study drugs that confers a risk of patient safety if the patient participates in the trial and adheres to the protocol-specified recommendations, per the assessment of the treating physician 6. Life expectancy less than one year 7. Pregnancy or women of childbearing potential who is not sterilized or is not using a medically accepted form of contraception

Primary outcome measure(s)

  • Measurement of Global longitudinal strain (GLS, %) — day 7±24 hours
    GLS adjusted for baseline.

Trial sites (1)

FacilityCityRegionStatus
Sahlgrenska University Hospital Gothenburg Sweden Recruiting

More Vastra Gotaland Region trials in Sweden

Nutrition in Rheumatoid Arthritis Enrolling by invitation
The Impact of Low Versus High Positive End-expiratory Pressure on Diaphragm Function, Ventilation Efficiency, and Lung Mechanics Recruiting
Autologous vs. Implant-based Breast Reconstruction Recruiting
A New Cancer Rehabilitation Process for Chemotherapy-Induced Foot Neuropathy Using Orthopedic Devices Recruiting
Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06562582 on ClinicalTrials.gov ↗ ← All trials in Sweden